Genetic Changes of P53 and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand

Shukla, Sanjeev K.; Singh, Govind; Shahi, K. S.; Bhuvan,; Pant, Prabhat

doi:10.1007/s12029-019-00283-0

Cited by 12 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of 92 articles, 30 were excluded due to: no data for adenocarcinoma of the gallbladder available (N = 12), overlapping cohorts (N = 8), the wrong type of article (N = 5), no genetic alteration frequency data available (N = 3), wrong study population (N = 1), and not written in English (N = 1). A total of 62 articles were included for final data extraction, describing a total of 3893 GBC samples from individual patients [ 18 , 19 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ,…”

Section: Resultsmentioning

confidence: 99%

“… Japan Nagai 2002 [ 24 ] 10/20 50% PCR + RFLP and DS N.A. Korea Kim 2000 [ 50 ] 12/25 48% PCR-RFLP AC India Shukla 2020 [ 34 ] 16/39 41% PCR-RFLP N.A. India Kazmi 2013 [ 71 ] 72/760 9% NGS N.A.…”

Section: Table A1mentioning

confidence: 99%

“… America Borger 2012 [ 30 ] 2/4 50% TS AC Korea Yoo 2016 [ 37 ] 2/11 18% ultra-deep targeted NGS N.A. India Yadav 2017 [ 77 ] 3/5 60% WES AC Japan Akita 2019 [ 48 ] 4/46 9% mass array + seq AC India Kumari 2014 [ 34 ] 5/14 36% …”

Section: Table A1mentioning

confidence: 99%

“… China Li 2020 [ 47 ] 9/14 64% NGS N.A. Japan Noguchi 2017 [ 32 ] 17/40 43% nested PCR +DS AC Japan, Hungary Nagahashi 2008 [ 35 ] 11/25 44% PCR-SSCP AC India Shukla 2020 [ 34 ] 11/24 46% NGS N.A. America Okamura 2021 [ 27 ] 12/26 46% ...…”

Section: Table A1mentioning

confidence: 99%

See 3 more Smart Citations

Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications

Kuipers

Bitter

Boer

et al. 2021

Cancers

View full text Add to dashboard Cite

Due to the fast progression in molecular technologies such as next-generation sequencing, knowledge of genetic alterations in gallbladder cancer (GBC) increases. This systematic review provides an overview of frequently occurring genetic alterations occurring in GBC and their possible therapeutic implications. A literature search was performed utilizing PubMed, EMBASE, Cochrane Library, and Web of Science. Only studies reporting genetic alterations in human GBC were included. In total, data were extracted from 62 articles, describing a total of 3893 GBC samples. Frequently detected genetic alterations (>5% in >5 samples across all studies) in GBC for which targeted therapies are available in other cancer types included mutations in ATM, ERBB2, and PIK3CA, and ERBB2 amplifications. High tumor mutational burden (TMB-H) and microsatellite instability (MSI-H) were infrequently observed in GBC (1.7% and 3.5%, respectively). For solid cancers with TMB-H or MSI-H pembrolizumab is FDA-approved and shows an objective response rates of 50% for TMB-H GBC and 41% for MSI-H biliary tract cancer. Only nine clinical trials evaluated targeted therapies in GBC directed at frequently altered genes (ERBB2, ARID1A, ATM, and KRAS). This underlines the challenges to perform such clinical trials in this rare, heterogeneous cancer type and emphasizes the need for multicenter clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Table A1mentioning

confidence: 99%

Section: Table A1mentioning

confidence: 99%

Section: Table A1mentioning

confidence: 99%

See 2 more Smart Citations

Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications

Kuipers

Bitter

Boer

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Overexpression and high mutation frequency of p53 protein, which has tumor-promoting signature rather than cell apoptotic activity, were correlated with a poor survival of a broad type of cancers, including GBC, 307 – 309 thus serving as a cancer biomarker. We previously analyzed GBC mutagenesis and found that TP53 was ranked as the top one in a large spectrum of mutated genes in GBC.…”

Section: Targeted Therapy Of Gbcmentioning

confidence: 99%

Overview of current targeted therapy in gallbladder cancer

Song

et al. 2020

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor. Unfortunately, only a small population of cancer patients is acceptable for the surgical resection, the current effective regimen; thus, the high mortality rate has been static for decades. To substantially circumvent the stagnant scenario, a number of therapeutic approaches owing to the creation of advanced technologic measures (e.g., next-generation sequencing, transcriptomics, proteomics) have been intensively innovated, which include targeted therapy, immunotherapy, and nanoparticle-based delivery systems. In the current review, we primarily focus on the targeted therapy capable of specifically inhibiting individual key molecules that govern aberrant signaling cascades in GBC. Global clinical trials of targeted therapy in GBC are updated and may offer great value for novel pathologic and therapeutic insights of this deadly disease, ultimately improving the efficacy of treatment.

show abstract